Oxford BioTherapeutics Licenses BioWa's POTELLIGENT(R) Technology for the Research and Development of its Therapeutic Antibodies in Cancer

PRINCETON, New Jersey and OXFORD, England, April 6, 2011 - BioWa, Inc. (BioWa) and Oxford BioTherapeutics Ltd (OBT) today
announced that they have entered into a license agreement to provide OBT with
access to BioWa's patented POTELLIGENT(R) Technology platform for the
development of antibody-dependent cellular cytotoxicity (ADCC) enhanced
antibodies.

OBT intends to use POTELLIGENT(R) Technology to develop,
manufacture and commercialize selected ADCC programs from its pipeline of
preclinical antibodies for oncology which it has built based upon novel
targets identified using its OGAP(R) proteomic database.

In return for the license, OBT will pay to BioWa undisclosed
license fees, development and commercialization milestones and royalties on
sales of any products that it commercializes.

"We are delighted to have access to BioWa's POTELLIGENT(R)
Technology as part of our technology access portfolio as we build a pipeline
of first-in-class therapeutic antibodies for cancer" said Christian Rohlff,
CEO of OBT. "Our strategy is to combine novel proprietary oncology targets
with world-leading antibody technologies, such as POTELLIGENT(R) Technology,
to develop highly efficacious new cancer drugs for patients with few
treatment options."

"The OBT cancer specific antibody portfolio has matured to an
advanced stage where coupling to BioWa's POTELLIGENT(R) Technology enhances
already promising anticancer agents and further enables our clinical
development pipeline", commented OBT's Senior Vice President of Oncology, Jon
Terrett.

"We are excited to expand our set of small company arrangements with OBT.
In large part, our decision to partner with OBT was driven by our interest in
novel therapeutic antibody targets identified through the OGAP(R) proteomic
database," said Yasunori Yamaguchi, President and CEO of BioWa.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of
antibody therapeutics, by enhancing ADCC, one of the major mechanisms of
action for antibody therapeutics. POTELLIGENT(R) Technology involves the
reduction of the amount of fucose in the carbohydrate structure of an
antibody using a proprietary fucosyl transferase-knockout CHO cell line as a
production cell. Research shows that POTELLIGENT(R) Technology dramatically
enhances ADCC activity of an antibody in vitro, and significantly increases
potency and efficacy of the antibody in vivo. A number of POTELLIGENT(R)
antibodies are being investigated in human clinical trials.

About BioWa

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co.,
Ltd., Japan's leading pharmaceutical and largest biotech company, and is the
exclusive worldwide licensor of AccretaMab(R) platform. AccretaMab(R)
platform consists of POTELLIGENT(R) and COMPLEGENT(R) Technologies, creating
a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is
offering POTELLIGENT(R) and COMPLEGENT(R) Technologies to partners under a
license to maximize the value of these technologies. Together with Kyowa
Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal
antibody-based therapeutics to fight cancer and other life-threatening and
debilitating diseases. For more information about BioWa, visit its web site
at www.biowa.com.

POTELLIGENT(R), COMPLEGENT(R), and AccretaMab(R) are the
trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is focused on the development of
targeted medicines for oncology. OBT's strategy is to develop innovative
antibody-based cancer drugs, with integrated diagnostics, against novel
targets that it has discovered in its unique OGAP(R) proteomic database.

OBT, through its alliances with the world leaders in antibody
development, has been able to use its unique position to convert its novel
targets into a highly attractive pipeline of therapeutic antibodies. OBT's
pipeline will deliver innovative and cost-effective medicines to fulfil major
unmet patient needs in the field of cancer.

OBT, a privately held company, was formed in 2004 and is based
near Oxford, UK.

For further information, please see
www.OxfordBioTherapeutics.com or www.oxbt.co.uk

About OGAP(R)

The Oxford Genome Anatomy Project (OGAP(R)) database
represents the world's largest proprietary collection of disease-associated
proteins. OGAP(R) oncology contains proteomic data on 5,000 cancer membrane
proteins combined with their genomic and clinical information derived from
human blood and cancer tissue studies. OGAP(R) contains proprietary target
information on three quarters of the entire human proteome. Over one million
human protein fragments have been sequenced in OGAP in 50 different human
tissues representing 60 diseases have been mapped to approximately 15,000
different genes and over eight million SNPs and haplotypes.

OGAP(R) is a registered trade mark of Oxford BioTherapeutics
Ltd.

    BioWa Enquiries
    President and CEO:
    Yasunori Yamaguchi, Ph.D.
    +1-609-580-7500

    Oxford BioTherapeutics Enquiries:
    Chief Executive Officer:
    Christian Rohlff, Ph.D.
    +(44)-(0)1235-861770
    E-mail: cr@oxbt.co.uk

    Media enquiries/Citigate:
    David Dible
    +(44)-(0)207-638-9571
    E-mail: david.dible@citigatedr.co.uk

BioWa Enquiries, President and CEO: Yasunori Yamaguchi, Ph.D., +1-609-580-7500. Oxford BioTherapeutics Enquiries: Chief Executive Officer: Christian Rohlff, Ph.D., +(44)-(0)1235-861770, E-mail: cr at oxbt.co.uk. Media enquiries/Citigate: David Dible, +(44)-(0)207-638-9571, E-mail: david.dible at citigatedr.co.uk